

Summary of risk management plan for Ceolat 10 mg-Injektionslösung (Metoclopramide hydrochloride)

This is a summary of the risk management plan (RMP) for Ceolat 10 mg-Injektionslösung. The RMP details important risks of Ceolat 10 mg-Injektionslösung, how these risks can be minimised, and how more information will be obtained about Ceolat 10 mg-Injektionslösung's risks and uncertainties (missing information).

The summary of product characteristics (SmPC) and package leaflet give essential information to healthcare professionals and patients on how Ceolat 10 mg-Injektionslösung should be used.

Important new concerns or changes to the current ones will be included in updates of Ceolat 10 mg-Injektionslösung's RMP.

I. The medicine and what it is used for

Ceolat 10 mg-Injektionslösung is authorised for the treatment of:

Adult population

- Prevention of post-operative nausea and vomiting (PONV)
- Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting
- Prevention of radiotherapy induced nausea and vomiting (RINV)

Paediatric population

- Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option
- The treatment of established post-operative nausea and vomiting (PONV) as a second line option

The solution for injection contains metoclopramide hydrochloride as the active substance and is given via the intramuscular (i.m.) or intravenous (i.v.) route. The solution for injection is available in a strength of 5 mg/ml.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Ceolat 10 mg-Injektionslösung, together with measures to minimise such risks and the proposed studies for learning more about Ceolat 10 mg-Injektionslösung's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Ceolat 10 mg-Injektionslösung are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use Ceolat 10 mg-Injektionslösung. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation.

Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Ceolat 10 mg-Injektionslösung.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Ceolat 10 mg-Injektionslösung.